Pharma Mar (NASDAQ:PHMMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Pharma Mar (PHMMF) opened at 4.50 on Friday. Pharma Mar has a 12-month low of $2.22 and a 12-month high of $4.80. The company’s market cap is $1.12 billion. The stock’s 50 day moving average is $4.47 and its 200-day moving average is $3.88.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/20/zacks-investment-research-lowers-pharma-mar-phmmf-to-hold.html.

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.